Form 4: Omeros Director Diana Perkinson Receives Annual Stock Option Grant

Omeros Corporation Director Diana T. Perkinson was granted 15,000 stock options as part of the company's non-employee director compensation policy.

Summary

• Diana T. Perkinson, a Director of Omeros Corporation (OMER), received an automatic annual stock option award.
• The grant, made on June 27, 2025, is for 15,000 shares of common stock.
• The exercise price for these options is $3.20 per share.
• The options will fully vest and become exercisable on the day before the 2026 annual meeting of shareholders, contingent on Ms. Perkinson's continued service as a director.
• The options have an expiration date of June 27, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine, expected compensation event for a director, which is generally neutral but can be seen as slightly positive due to alignment of interests.

Positives

• The grant aligns the director's financial interests with those of the shareholders, as the options gain value if the stock price increases.
• It reflects a standard compensation practice for non-employee directors, indicating stable corporate governance.

Negatives

• No specific negatives are indicated in this routine compensation filing.

Risks

• No specific risks are mentioned in this transactional filing.

Future Outlook

The options are subject to future vesting, contingent on the director's continued service until the day before the 2026 annual meeting.

Management Comments

• Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock.
• This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Industry Context

Granting stock options to non-employee directors is a common practice across various industries, including biotechnology, to incentivize long-term commitment and align their interests with shareholder value creation.

Comparison to Industry Standards

• This type of annual stock option grant to non-employee directors is a standard compensation mechanism in publicly traded companies, particularly within the biotech and pharmaceutical sectors, aiming to attract and retain qualified board members.
• While specific grant sizes vary by company size and policy, a grant of 15,000 options is within typical ranges for a director at a company like Omeros. No specific comparable companies or projects are mentioned in the document.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, as the options' value is tied to the company's stock performance.

Next Steps

• Continued service of Diana T. Perkinson as a director until the day before the 2026 annual meeting for the options to vest.
• Potential exercise of the options by Diana T. Perkinson after vesting and before expiration.

Key Dates

Keywords

Omeros, OMER, Form 4, stock option, director compensation, insider transaction, equity grant, corporate governance